Immuneering (NASDAQ:IMRX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Immuneering (NASDAQ:IMRX) from a hold rating to a sell rating in a report issued on Monday.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald assumed coverage on shares of Immuneering in a report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Finally, Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Immuneering Stock Performance

Shares of IMRX opened at $4.47 on Monday. The firm has a market cap of $289.21 million, a PE ratio of -3.82 and a beta of 0.41. The firm’s 50 day moving average price is $4.78 and its 200 day moving average price is $5.07. Immuneering has a twelve month low of $2.90 and a twelve month high of $10.08.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. On average, sell-side analysts anticipate that Immuneering will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Immuneering

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of Immuneering during the first quarter worth approximately $32,000. Geode Capital Management LLC increased its position in Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after acquiring an additional 4,458 shares during the period. XTX Topco Ltd acquired a new position in Immuneering during the 2nd quarter valued at $90,000. Bridgeway Capital Management LLC boosted its holdings in Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after purchasing an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC bought a new stake in Immuneering in the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.